Recently, PARP‐1 inhibitors have been introduced to the armamentarium of anti‐cancer drugs with the concept of rendering tumours more susceptible to single‐strand DNA breaks caused by chemotherapy and radiotherapy [51, 52]. The gene discussed is PARP1; the disease is cancer.